Fairfield Financial Advisors LTD Sells 146 Shares of AstraZeneca PLC (NASDAQ:AZN)

Fairfield Financial Advisors LTD reduced its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,832 shares of the company’s stock after selling 146 shares during the quarter. Fairfield Financial Advisors LTD’s holdings in AstraZeneca were worth $221,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of AZN. Price T Rowe Associates Inc. MD grew its holdings in shares of AstraZeneca by 17.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after purchasing an additional 9,002,450 shares in the last quarter. Swedbank AB acquired a new stake in shares of AstraZeneca during the 1st quarter worth $186,127,000. Manning & Napier Advisors LLC acquired a new stake in shares of AstraZeneca during the 2nd quarter worth $188,476,000. Hsbc Holdings PLC grew its holdings in shares of AstraZeneca by 750.3% during the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock worth $100,523,000 after purchasing an additional 1,132,362 shares in the last quarter. Finally, Farallon Capital Management LLC grew its holdings in shares of AstraZeneca by 65.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock worth $187,934,000 after purchasing an additional 950,000 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Trading Down 2.2 %

Shares of AZN stock traded down $1.61 during mid-day trading on Thursday, reaching $71.22. 2,866,558 shares of the stock traded hands, compared to its average volume of 5,003,007. The stock’s fifty day simple moving average is $79.77 and its two-hundred day simple moving average is $78.64. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The company has a market cap of $220.82 billion, a price-to-earnings ratio of 35.18, a price-to-earnings-growth ratio of 1.39 and a beta of 0.46. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69.

Analysts Set New Price Targets

AZN has been the topic of several research analyst reports. TD Cowen raised their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.